The greater beneficial cardiovascular effects and superior clinical efficacy in the glycemic control and improving obesity achieved by therapies using GLP-1 analogs/GLP-1R agonists than those by DPP4 inhibition, presumably due to relatively and pharmacologically higher efficacy in the activation of the GLP-1R in these subjects on GLP-1 analogs/GLP-1R agonist therapies. Here, GLP1R is linked to obesity disorder.